Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Catherine C Smith, MD, Kimberly Lin, BS, Elisabeth Lasater, PhD, Whitney Stewart, BS, Lauren E Damon, Andrew Kasarskis, PhD, Ali Bashir, PhD, Matthew Pendleton, Robert Sebra, Alexander E Perl, MD, Mai H Le, MD, Chao Zhang, PhD, Brian West, Ph.D., Neil P. Shah, MD, PhD

Blood (2013) 122 (21): 3938.

https://doi.org/10.1182/blood.V122.21.3938.3938

Published: 2013

Journal Articles

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara Salerno, Neil P. Shah

Blood (2013) 121 (16): 3165–3171.

https://doi.org/10.1182/blood-2012-07-442871

Published: 2013

Includes: Supplemental data

Journal Articles

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Catherine C Smith, MD, Elisabeth Lasater, PhD, Melissa Mccreery, BS, Kimberly Lin, BS, Whitney Stewart, BS, Lauren E Damon, Alexander E Perl, MD, Grace R Jeschke, Mayumi Sugita, MD, Martin Carroll, MD, Scott C. Kogan, MD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 141.

https://doi.org/10.1182/blood.V120.21.141.141

Published: 2012

Journal Articles

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Catherine C Smith, MD, Jason Chin, PhD, Elisabeth Lasater, PhD, Amy L. Paguirigan, PhD, Kimberly Lin, BS, Whitney Stewart, BS, Sara Salerno, BS, Lauren E Damon, Mark J. Levis, MD, PhD, Alexander E Perl, MD, Kevin Travers, PhD, Andrew Kasarskis, PhD, Jerald P. Radich, MD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 674.

https://doi.org/10.1182/blood.V120.21.674.674

Published: 2012

Journal Articles

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

Catherine C. Smith, MD, Lauren E. Damon, Xiaotian Zhu, PhD, Sara Salerno, BS, Neil Shah, MD, PhD

Blood (2011) 118 (21): 930.

https://doi.org/10.1182/blood.V118.21.930.930

Published: 2011

Journal Articles

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro

Catherine C. Smith, MD, Alexander E Perl, MD, Elisabeth Lasater, PhD, Chao Zhang, PhD, Grace R Jeschke, Lauren E. Damon, Martin Carroll, MD, Neil P. Shah, MD, PhD

Blood (2011) 118 (21): 764.

https://doi.org/10.1182/blood.V118.21.764.764

Published: 2011

Journal Articles

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Catherine C. Smith, MD, Jason Chin, PhD, Qi Wang, PhD, Sara Salerno, BS, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, MD, PhD, Alexander E Perl, MD, Kevin Travers, PhD, Susana Wang, Andrew Kasarskis, PhD, Eric Schadt, PhD, John Kuriyan, PhD, Neil Shah, MD, PhD

Blood (2011) 118 (21): 937.

https://doi.org/10.1182/blood.V118.21.937.937

Published: 2011

Journal Articles

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Warren Fiskus, BSc, PhD, Catherine C. Smith, MD, Jacqueline Smith, MS, Scott C. Wise, MS, Elisabeth Lasater, PhD, Lauren E. Damon, Sara Salerno, BS, Allan Fleming, MD, Ruben Reyes, MD, Siddhartha Ganguly, MD, Mark S. Berger, MD, Tom J. Rutkoski, Ph.D, Joseph McGuirk, DO, Neil Shah, MD, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2611.

https://doi.org/10.1182/blood.V118.21.2611.2611

Published: 2011

Journal Articles

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,

Catherine C. Smith, MD, Michael Brown, PhD, Jason Chin, PhD, Corynn Kasap, BS, Sara Salerno, BS, Lauren E. Damon, Kevin Travers, PhD, Susana Wang, Andrew Kasarskis, PhD, Eric Schadt, PhD, Neil Shah, MD, PhD

Blood (2011) 118 (21): 3752.

https://doi.org/10.1182/blood.V118.21.3752.3752

Published: 2011

NARROW

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only